MedTrace Logo

Improving Breast Health Knowledge Among Women Using a Gamified Metaverse-Based Platform

NCT06930898 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-04-18

No results posted yet for this study

Summary

This randomized controlled trial aimed to evaluate the effectiveness of Mammoverse, a gamified metaverse-based educational platform, in improving breast health knowledge among women in China. Participants were randomly assigned to either a gamified or non-gamified version of the platform. Both groups received identical educational content, but only the gamified group experienced interactive game elements such as avatars, progress feedback, and rewards. Knowledge was assessed at baseline, immediately post-intervention, and at 4-week follow-up. The study found that the gamified platform significantly improved knowledge retention and participant engagement compared to the non-gamified version.

This ClinicalTrials.gov registration reflects only the randomized controlled trial (RCT) portion of a broader mixed-methods study that was approved by the University of Malaya Research Ethics Committee (Ref: UM.TNC2/UMREC\_3967). The full study protocol includes three methodological approaches, and this registration pertains specifically to the RCT component involving the Mammoverse platform. Other study components are not included in this registration.

Conditions

  • Health Education
  • Breast Neoplasms

Interventions

BEHAVIORAL

Gamified Mammoverse Platform

A gamified, metaverse-based platform delivering breast health education through story-based tasks, interactive challenges, points, rewards, badges, and virtual incentives.

BEHAVIORAL

Standard Mammoverse Platform

A non-gamified version of the Mammoverse platform that provides the same breast health educational content.

Sponsors & Collaborators

  • University of Malaya

    lead OTHER

Principal Investigators

  • Rui Li, PhD(c) · University of Malaya

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-02-01
Completion
2025-03-24

Countries

  • China
  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06930898 on ClinicalTrials.gov